The NF-κB inhibitor, SC75741, is a novel antiviral against emerging tick-borne bandaviruses

Crystal A. Mendoza, Satoko Yamaoka, Yoshimi Tsuda, Keita Matsuno, Carla M. Weisend, Hideki Ebihara

Research output: Contribution to journalArticlepeer-review

Abstract

Severe fever with thrombocytopenia syndrome virus (SFTSV) and Heartland virus (HRTV) cause viral hemorrhagic fever-like illnesses in humans due to an aberrant host inflammatory response, which contributes to pathogenesis. Here, we established two separate minigenome (MG) systems based on the M-segment of SFTSV and HRTV. Following characterization of both systems for SFTSV and HRTV, we used them as a platform to screen potential compounds that inhibit viral RNA synthesis. We demonstrated that the NF-κB inhibitor, SC75741, reduces viral RNA synthesis of SFTSV and HRTV using our MG platform and validated these results using infectious SFTSV and HRTV. These results may lead to the use of MG systems as potential screening systems for the identification of antiviral compounds and yield novel insights into host-factors that could play role in bandavirus transcription and replication.

Original languageEnglish (US)
Article number104993
JournalAntiviral Research
Volume185
DOIs
StatePublished - Jan 2021

Keywords

  • And minigenome
  • Antiviral
  • Bandavirus
  • Heartland virus
  • Severe fever with thrombocytopenia syndrome virus

ASJC Scopus subject areas

  • Pharmacology
  • Virology

Fingerprint Dive into the research topics of 'The NF-κB inhibitor, SC75741, is a novel antiviral against emerging tick-borne bandaviruses'. Together they form a unique fingerprint.

Cite this